NCT01227317

BIOmarkers of Dyspnea IN Emergency Room

Prognostic Value of Novel Biomarkers in Patients With Shortness of Breath Attending an Emergency Department

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 444 (actual)
• Sponsor: ThermoFisher Scientific Brahms Biomarkers France · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine vasopressin), Pro endothelin to stratify the risk in severe dyspnea.

Detailed description

In emergency department shortness of breath (SOB)is a common symptom and its cause is not easy to be identified. The risk stratifying remains a challenge, Prognostic value of biomarkers might be helpful.

Conditions

• Severe Dyspnea
• CAPD
• AE COPD
• Acute Heart Failure
• Pulmonary Embolism

Interventions

Type	Name	Description
OTHER	Prognostic value of Biomarkers	Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients

Timeline

• Start date: 2010-04-01
• Primary completion: 2011-08-01
• Completion: 2011-09-01
• First posted: 2010-10-25
• Last updated: 2011-12-07

Locations

1 site across 1 country: France